Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease

British Journal of Pharmacology

Volumn 164, Issue 8, 2011, Pages 2029-2041

  Cuadrado Tejedor, M ^a   Hervias, I ^b   Ricobaraza, A ^a   Puerta, E ^b   Perez Roldan J M ^a   Garcia Barroso C ^a   Franco, R ^a   Aguirre, N ^b   Garcia Osta A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Alzheimer's disease; BDNF; CDK5; GSK3 ; p tau; sildenafil

Indexed keywords

ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN P25; PROTEIN P35; SILDENAFIL; SODIUM CHLORIDE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BIOCHEMISTRY; BRAIN FUNCTION; CELL LYSATE; COGNITIVE DEFECT; CONDITIONING; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEAR; FUNCTIONAL ASSESSMENT; HIPPOCAMPUS; HUMAN; MAZE TEST; MEMORY DISORDER; MENTAL TASK; MOUSE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION; CYTOSKELETAL PROTEINS; FEAR; IMMUNOHISTOCHEMISTRY; MAZE LEARNING; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; TAU PROTEINS;

EID: 81855203432     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01517.x     Document Type: Article

References (77)

1. Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, Mccarthy S, et al,. (2000). Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 97: 2910-2915. (Pubitemid 30159271)
2. Alvarez A, Munoz JP, Maccioni RB, (2001). A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons. Exp Cell Res 264: 266-274. (Pubitemid 32980231)
3. Avila J, Hernandez F, (2007). GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother 7: 1527-1533. (Pubitemid 350106832)
4. Bernabeu R, Bevilaqua L, Ardenghi P, Bromberg E, Schmitz P, Bianchin M, et al,. (1997). Involvement of hippocampal cAMP/cAMP-dependent protein kinase signaling pathways in a late memory consolidation phase of aversively motivated learning in rats. Proc Natl Acad Sci USA 94: 7041-7046. (Pubitemid 27281987)
5. Dash PK, Hochner B, Kandel ER, (1990). Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation. Nature 345: 718-721.
6. Devan BD, Sierra-Mercado D Jr, Jimenez M, Bowker JL, Duffy KB, Spangler EL, et al,. (2004). Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol Biochem Behav 79: 691-699. (Pubitemid 39600608)
7. Devan BD, Bowker JL, Duffy KB, Bharati IS, Jimenez M, Sierra-Mercado D, et al,. (2006). Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition. Psychopharmacology (Berl) 183: 439-445. (Pubitemid 41721145)
8. Devan BD, Pistell PJ, Daffin LW Jr, Nelson CM, Duffy KB, Bowker JL, et al,. (2007). Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nomega-nitro-L-arginine methyl ester. Eur J Pharmacol 563: 134-140. (Pubitemid 46628798)
9. Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, Morgan D, (2003). Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci 23: 5219-5526.
10. Dickey CA, Gordon MN, Mason JE, Wilson NJ, Diamond DM, Guzowski JF, et al,. (2004). Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. J Neurochem 88: 434-442. (Pubitemid 38084559)
11. Dineley KT, Xia X, Bui D, Sweatt JD, Zheng H, (2002). Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 277: 22768-22780. (Pubitemid 34967257)
12. Dodart JC, Bales KR, Gannon KS, Greene SJ, Demattos RB, Mathis C, et al,. (2002). Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5: 452-457. (Pubitemid 34454251)
13. Elyaman W, Terro F, Wong NS, Hugon J, (2002). In vivo activation and nuclear translocation of phosphorylated glycogen synthase kinase-3beta in neuronal apoptosis: links to tau phosphorylation. Eur J Neurosci 15: 651-660. (Pubitemid 35471934)
14. Frey U, Huang YY, Kandel ER, (1993). Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 260: 1661-1664. (Pubitemid 23247151)
15. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al,. (2003). Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60: 1495-1500. (Pubitemid 36559525)
16. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O, (2004). Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114: 1624-1634. (Pubitemid 40385553)
17. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al,. (2009). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302: 2557-2564.
18. Guzowski JF, (2002). Insights into immediate-early gene function in hippocampal memory consolidation using antisense oligonucleotide and fluorescent imaging approaches. Hippocampus 12: 86-104. (Pubitemid 34211250)
19. Guzowski JF, Mcgaugh JL, (1997). Antisense oligodeoxynucleotide-mediated disruption of hippocampal cAMP response element binding protein levels impairs consolidation of memory for water maze training. Proc Natl Acad Sci USA 94: 2693-2698. (Pubitemid 27136938)
20. Guzowski JF, Mcnaughton BL, Barnes CA, Worley PF, (1999). Environment-specific expression of the immediate-early gene Arc in hippocampal neuronal ensembles. Nat Neurosci 2: 1120-1124. (Pubitemid 30126371)
21. Haghikia A, Mergia E, Friebe A, Eysel UT, Koesling D, Mittmann T, (2007). Long-term potentiation in the visual cortex requires both nitric oxide receptor guanylyl cyclases. J Neurosci 27: 818-823. (Pubitemid 46174500)
22. Han JH, Kushner SA, Yiu AP, Cole CJ, Matynia A, Brown RA, et al,. (2007). Neuronal competition and selection during memory formation. Science 316: 457-460. (Pubitemid 46651495)
23. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH, (1992). Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147: 58-62.
24. Hanger DP, Anderton BH, Noble W, (2009). Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15: 112-119.
25. Hartell NA, (1996). Inhibition of cGMP breakdown promotes the induction of cerebellar long-term depression. J Neurosci 16: 2881-2890.
26. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al,. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102. (Pubitemid 26332733)
27. Huang HC, Klein PS, (2006). Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease. Curr Drug Targets 7: 1389-1397. (Pubitemid 44718299)
28. Impey S, Mark M, Villacres EC, Poser S, Chavkin C, Storm DR, (1996). Induction of CRE-mediated gene expression by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron 16: 973-982.
29. Ishiguro K, Shiratsuchi A, Sato S, Omori A, Arioka M, Kobayashi S, et al,. (1993). Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett 325: 167-172. (Pubitemid 23186470)
30. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, et al,. (1997). Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 94: 1550-1555.
31. Josselyn SA, Shi C, Carlezon WA Jr, Neve RL, Nestler EJ, Davis M, (2001). Long-term memory is facilitated by cAMP response element-binding protein overexpression in the amygdala. J Neurosci 21: 2404-2412. (Pubitemid 32240537)
32. Koh SH, Kim Y, Kim HY, Hwang S, Lee CH, Kim SH, (2007). Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp Neurol 205: 336-346. (Pubitemid 46755762)
33. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al,. (2004). Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24: 10191-10200. (Pubitemid 39492046)
34. Lau LF, Seymour PA, Sanner MA, Schachter JB, (2002). Cdk5 as a drug target for the treatment of Alzheimer's disease. J Mol Neurosci 19: 267-273. (Pubitemid 36051517)
35. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH, (2000). Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405: 360-364. (Pubitemid 30337070)
36. Lee KW, Lee SH, Kim H, Song JS, Yang SD, Paik SG, et al,. (2004). Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein. J Neurosci Res 76: 572-580. (Pubitemid 38580472)
37. Liu F, Iqbal K, Grundke-Iqbal I, Gong CX, (2002). Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett 530: 209-214. (Pubitemid 35248213)
38. Lopes JP, Oliveira CR, Agostinho P, (2007). Amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies. Cell Mol Neurobiol 27: 943-957.
39. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, et al,. (1998). Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216: 139-147. (Pubitemid 28389111)
40. Lu YF, Kandel ER, Hawkins RD, (1999). Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci 19: 10250-10261. (Pubitemid 30228032)
41. Lyford GL, Yamagata K, Kaufmann WE, Barnes CA, Sanders LK, Copeland NG, et al,. (1995). Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron 14: 433-445.
42. Malm TM, Iivonen H, Goldsteins G, Keksa-Goldsteine V, Ahtoniemi T, Kanninen K, et al,. (2007). Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J Neurosci 27: 3712-3721. (Pubitemid 46557689)
43. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, Vandenheede JR, et al,. (1992). Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 314: 315-321. (Pubitemid 23005680)
44. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al,. (2009). Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15: 331-337.
45. Otth C, Concha I, Arendt T, Stieler J, Schliebs R, Gonzalez-Billault C, et al,. (2002). AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis 4: 417-430. (Pubitemid 35397807)
46. Patil CS, Singh VP, Kulkarni SK, (2006). Modulatory effect of sildenafil in diabetes and electroconvulsive shock-induced cognitive dysfunction in rats. Pharmacol Rep 58: 373-380. (Pubitemid 44111072)
47. Patrick GN, Zukerberg L, Nikolic M, De La Monte S, Dikkes P, Tsai LH, (1999). Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402: 615-622. (Pubitemid 129516324)
48. Paul C, Schoberl F, Weinmeister P, Micale V, Wotjak CT, Hofmann F, et al,. (2008). Signaling through cGMP-dependent protein kinase I in the amygdala is critical for auditory-cued fear memory and long-term potentiation. J Neurosci 28: 14202-14212.
49. Plattner F, Angelo M, Giese KP, (2006). The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281: 25457-25465. (Pubitemid 44401934)
50. Price JL, Morris JC, (1999). Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol 45: 358-368. (Pubitemid 29120041)
51. Prickaerts J, De Vente J, Honig W, Steinbusch HW, Blokland A, (2002a). cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. Eur J Pharmacol 436: 83-87. (Pubitemid 34142401)
52. Prickaerts J, Van Staveren WC, Sik A, Markerink-Van Ittersum M, Niewohner U, Van Der Staay FJ, et al,. (2002b). Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 113: 351-361. (Pubitemid 34786180)
53. Puerta E, Hervias I, Goni-Allo B, Lasheras B, Jordan J, Aguirre N, (2009). Phosphodiesterase 5 inhibitors prevent 3,4- methylenedioxymethamphetamine-induced 5-HT deficits in the rat. J Neurochem 108: 755-766.
54. Puerta E, Hervias I, Barros-Minones L, Jordan J, Ricobaraza A, Cuadrado-Tejedor M, et al,. (2010). Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol Dis 38: 237-245.
55. Puzzo D, Staniszewski A, Deng SX, Privitera L, Leznik E, Liu S, et al,. (2009). Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J Neurosci 29: 8075-8086.
56. Reagan-Shaw S, Nihal M, Ahmad N, (2008). Dose translation from animal to human studies revisited. FASEB J 22: 659-661. (Pubitemid 351348146)
57. Reed MN, Liu P, Kotilinek LA, Ashe KH, (2010). Effect size of reference memory deficits in the Morris water maze in Tg2576 mice. Behav Brain Res 212: 115-120.
58. Reyes-Irisarri E, Perez-Torres S, Mengod G, (2005). Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 132: 1173-1185. (Pubitemid 40602550)
59. Ricobaraza A, Cuadrado-Tejedor M, Perez-Mediavilla A, Frechilla D, Del Rio J, Garcia-Osta A, (2009). Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 34: 1721-1732.
60. Ricobaraza A, Cuadrado-Tejedor M, Marco S, Perez-Otano I, Garcia-Osta A, (2010). Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus DOI: 10.1002/hipo.20883 [Epub ahead of print].
61. Rutten K, Vente JD, Sik A, Ittersum MM, Prickaerts J, Blokland A, (2005). The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behav Brain Res 164: 11-16. (Pubitemid 41253727)
62. Rutten K, Basile JL, Prickaerts J, Blokland A, Vivian JA, (2008). Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology 196: 643-648.
63. Sasaki A, Shoji M, Harigaya Y, Kawarabayashi T, Ikeda M, Naito M, et al,. (2002). Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament-typed, dystrophic neurites. Virchows Arch 441: 358-367. (Pubitemid 36015599)
64. Selkoe DJ, (2002). Alzheimer's disease is a synaptic failure. Science 298: 789-791. (Pubitemid 35231524)
65. Shepherd JD, Bear MF, (2011). New views of Arc, a master regulator of synaptic plasticity. Nat Neurosci 14: 279-284.
66. Son H, Lu YF, Zhuo M, Arancio O, Kandel ER, Hawkins RD, (1998). The specific role of cGMP in hippocampal LTP. Learn Mem 5: 231-245. (Pubitemid 29108882)
67. Stanciu M, Radulovic J, Spiess J, (2001). Phosphorylated cAMP response element binding protein in the mouse brain after fear conditioning: relationship to Fos production. Brain Res Mol Brain Res 94: 15-24. (Pubitemid 32964742)
68. Steward O, Worley PF, (2001). Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation. Neuron 30: 227-240. (Pubitemid 32441689)
69. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME, (1998). Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20: 709-726. (Pubitemid 28199050)
70. Thind K, Sabbagh MN, (2007). Pathological correlates of cognitive decline in Alzheimer's disease. Panminerva Med 49: 191-195.
71. Tomidokoro Y, Ishiguro K, Harigaya Y, Matsubara E, Ikeda M, Park JM, et al,. (2001). Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice. Neurosci Lett 299: 169-172. (Pubitemid 32124838)
72. Tsai LH, Lee MS, Cruz J, (2004). Cdk5, a therapeutic target for Alzheimer disease? Biochim Biophys Acta 1697: 137-142. (Pubitemid 38326767)
73. Tully T, Bourtchouladze R, Scott R, Tallman J, (2003). Targeting the CREB pathway for memory enhancers. Nat Rev Drug Discov 2: 267-277. (Pubitemid 37361685)
74. Twomey C, Mccarthy JV, (2006). Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate. FEBS Lett 580: 4015-4020. (Pubitemid 44037562)
75. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M, (2002). Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 99: 13217-13221.
76. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, et al,. (2002). The relationship between Aβeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 1: 1858-1867. (Pubitemid 35386304)
77. Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, et al,. (2002). Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33: 2675-2680. (Pubitemid 35266440)